Skip to main content
Caplight Logo









Hummingbird Bioscience

Hummingbird Bioscience

Private
SingaporeHealthcare & Life Scienceshttps://hummingbirdbioscience.com/

Last Round

Series C

May 18, 2021

Total Funding Raised

$182.1M

Company Overview

Hummingbird Bioscience is a biotechnology company that develops innovative therapeutic antibody-based drugs aimed at addressing the significant unmet needs of oncology and immuno-oncology patients.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

antibody discoveryprecision medicineimmuno-oncologycomputational biologydrug discoveryrational antibody discoveryRAD platformAI drug discoverybiotechtherapeutic antibodiesin silico drug designsystems biologyinflammatory diseasedrug licensingAI-first biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hummingbird Bioscience Comparables

Compare Hummingbird Bioscience with similar companies based on industry and business-model similarity.

Hummingbird Bioscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AbCellera Biologics Inc.
81%
Biolojic Design
81%
BenevolentAI
79%

Hummingbird Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMay 18, 2021
Series B ExtensionMay 10, 2020
Series BDec 4, 2019
Series A ExtensionJul 10, 2019
GrantFeb 21, 2019
Series A
May 3, 2017

Key People

Founding team and executive leadership

Jerome Boyd-Kirkup

Chief Scientific Officer Co-Founder

Founding Team

Konrad Paszkiewicz

Chief Technology Officer

Executive Team

Dipti Thakkar

Chief Operating Officer

Executive Team

Hummingbird Bioscience Investors

Notable investors and investment history

Hummingbird Bioscience investors
InvestorRounds
Heritas Capital ManagementSeries B, Series C, Series B Extension, Series A Extension
Cancer Prevention & Research Institute of TexasGrant
Frazier Healthcare PartnersSeries C
SEEDS CapitalSeries B, Series C, Series B Extension, Series A Extension
Mirae AssetSeries B, Series C
Octagon Capital AdvisorsSeries C
Ally Bridge GroupSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 15, 2025

    Clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity.

  • May 18, 2021

    $125M round led by Novo Holdings.

Recent news

Latest coverage and updates

  • partners_withSep 28, 2026

    Hummingbird Bioscience Pte Ltd. partners with LynxKite.

  • is_developingSep 28, 2026

    Hummingbird Bioscience Pte Ltd. is developing Toxicity Knowledge Graph.

  • hiresSep 15, 2026

    Hummingbird Bioscience Pte Ltd. hired James Garner as President on Sep 15th '26.

  • hiresSep 15, 2026

    Hummingbird Bioscience Pte Ltd. hired James Garner as President on Sep 15th '26.

  • attends_eventJul 14, 2026

    Hummingbird Bioscience Pte. Ltd. attended event AI Discovery Awards on Jul 14th '26.

Hummingbird Bioscience Filings

Explore SEC and related filing metadata, where available.

Hummingbird Bioscience filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Hummingbird Bioscience's valuation, stock price, and market status.

Is Hummingbird Bioscience a public or private company?

Hummingbird Bioscience is a private company.

What is the current stock price of Hummingbird Bioscience?

Hummingbird Bioscience is a private company with no public stock price. No recent secondary market data is available.

How much is Hummingbird Bioscience worth (valuation)?

Valuation information for Hummingbird Bioscience is not publicly available.

Can I buy Hummingbird Bioscience stock?

Hummingbird Bioscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Hummingbird Bioscience's last funding round?

Hummingbird Bioscience's most recent funding round was Series C on May 18, 2021.

Who are the main investors in Hummingbird Bioscience?

Key investors in Hummingbird Bioscience include Heritas Capital Management, SEEDS Capital, Mirae Asset, Mirae Asset Securities, Novo Holdings.

Will Hummingbird Bioscience IPO soon?

No public IPO plans have been announced for Hummingbird Bioscience.

How can I track Hummingbird Bioscience secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Hummingbird Bioscience's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSingapore
Employee Range70
Year Founded2015
Last FundingMay 18, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?